Datapoint: FDA Approves AbbVie’s Qulipta in Migraine Prevention

The FDA on Sept. 28 approved AbbVie’s CGRP inhibitor Qulipta for the prevention of episodic migraine, with analysts already calling the drug a blockbuster-to-be. Qulipta will have to face off against Biohaven’s Nurtec ODT, the first oral CGRP inhibitor approved in the migraine space. For migraine prevention, Nurtec holds covered or better status for 77% of all insured lives under the pharmacy benefit, and is not covered for 19.2% of lives.

SOURCE: MMIT Analytics, as of 10/6/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 6

Datapoint: Moda Health to Expand to Idaho

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 5

Datapoint: North Carolina Delays Launch of New Medicaid MCOs

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 4

Datapoint: FDA Approves Avastin Biosimilar

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today